Evommune IPO: shares in atopic dermatitis treatment developer become available

Preliminary trading in shares of Evommune, a developer of treatments for chronic inflammatory diseases, has begun on Freedom Finance's client trading system. The biotech company is at an important stage in the development of two of its key drugs. Later on Nov. 6, its securities will appear on the New York Stock Exchange under the ticker EVMN.

Biotech company Evommune has raised $150 million in an IPO. It placed 9.38 million shares at $16 - in the middle of the announced range. Based on the price and volume of the offering, the company's value can be estimated at about $481.2 billion, Bloomberg calculated.

The deal was organized by Morgan Stanley, Leerink Partners, Evercore ISI and Cantor.

Evommune's major shareholders are EQT Life Sciences and Pivotal bioVenture Partners, BiopharmaDive notes .

Evommune is creating oral therapeutics for the treatment of chronic inflammatory diseases. The company plans to use the funds raised in its IPO to further develop two drugs. The first, EVO756, is a tablet that blocks the receptor that causes itching and inflammation in chronic urticaria and atopic dermatitis, helping to relieve symptoms. The second, EVO301, is a protein drug that stays in the blood longer and reduces inflammation in atopic dermatitis and ulcerative colitis.

Both developments are undergoing Phase II clinical trials, that is, they are being tested on patients. At this stage, the first serious data on whether the drug works is usually obtained and it is decided whether it is worth continuing the study, Capital.com points out .

For 2024, Evommune had revenue of about $7 million and a net loss of about $66.8 million, according to listing application documents. As of June 30, 2025, the company had cash, cash equivalents and short-term investments totaling about $86.8 million.

The market for atopic dermatitis drugs is large and growing. It is estimated to reach $17.6 billion in 2024 and may expand to about $29.9 billion by 2030 at a compound annual growth rate of about 9%.

However, Evommune faces strong competition from large pharmaceutical companies and other biotech firms, notes Seeking Alpha IPO analyst Donovan Jones. Despite being well capitalized and backed by leading investors, he says, there remain significant risks associated with commercialization and valuation of the stock after the offering.

Evommune's focus on oral immune therapies rather than injectable biologics makes the company attractive to investors looking for differentiated healthcare assets, Capital.com says . Post-listing stock performance will depend on the company's clinical, financial and strategic success, as well as how the market views the risks of late-stage biotech companies, the publication explains. Strong data could cement Evommune's leadership in immunomodulatory dermatology.

Freedom Finance analyst Alem Bektemirov estimates the fair value of Biotech's shares at about $16.5. This implies a growth potential of 3% relative to the IPO price. The main risk for the company, according to him, is disapproval of drugs or weak research results, which could significantly affect the share price, as well as future competition in the market.

__________________

Freedom clients will be able to get access to Evommune shares before the opening of the main exchange session. Trading will begin in the early pre-market format 2-3 hours before the U.S. exchanges open (from 15:30-16:30 Astana time). To participate, click on ticker EVMN.

This article was AI-translated and verified by a human editor